CTC
UTHR icon

Central Trust Company’s United Therapeutics UTHR Stock Holding History

Central Trust Company’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Hold
32
– – ﹤0.01% 1108
2026
Q1 		$19K Hold
32
– – ﹤0.01% 1030
2025
Q4 		$15.7K Hold
32
– – ﹤0.01% 1039
2025
Q3 		$13.4K Hold
32
– – ﹤0.01% 1067
2025
Q2 		$9.2K Hold
32
– – ﹤0.01% 1131
2025
Q1 		$9.87K Hold
32
– – ﹤0.01% 1111
2024
Q4 		$11.3K Hold
32
– – ﹤0.01% 1083
2024
Q3 		$11.5K Hold
32
– – ﹤0.01% 1045
2024
Q2 		$10.2K Hold
32
– – ﹤0.01% 1063
2024
Q1 		$7.35K Hold
32
– – ﹤0.01% 1126
2023
Q4 		$7.04K Hold
32
– – ﹤0.01% 1113
2023
Q3 		$7.23K Hold
32
– – ﹤0.01% 1100
2023
Q2 		$7.06K Hold
32
– – ﹤0.01% 1067
2023
Q1 		$7.17K Hold
32
– – ﹤0.01% 1079
2022
Q4 		$8.9K Hold
32
– – ﹤0.01% 1026
2022
Q3 		$7K Hold
32
– – ﹤0.01% 1084
2022
Q2 		$8K Sell
32
-335
-91% -$68.1K ﹤0.01% 1079
2022
Q1 		$66K Buy
+367
New +$69.9K ﹤0.01% 762

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Central Trust Company's UTHR Position: Q2 2026 in Review

Central Trust Company held its United Therapeutics (UTHR) position steady in Q2 2026 at 32 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Central Trust Company first reported a position in UTHR in Q1 2022 and has held it in 18 quarters since. The position peaked at $66K in Q1 2022. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Central Trust Company held 32 shares of United Therapeutics worth $17.3K as of Q2 2026.
  • Central Trust Company left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1108 holding.
  • Central Trust Company first reported a position in United Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Central Trust Company's United Therapeutics position peaked at $66K in Q1 2022.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.